The development of multiple bladder tumor recurrences in relation to the FGFR3 mutation status of the primary tumor

被引：0
|
作者：
Kompier, Lucie
van Tilborg, Angela
van der Aa, Madelon
Lurkin, Irene
Vermeij, Marcel
Kirkels, Wim
Bangma, Chris
van der Kwast, Theo
Zwarthoff, Ellen
机构：
[1] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
[2] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[3] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1644
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway
    He, Y.
    Wu, X.
    Cao, Y.
    Hou, Y.
    Chen, H.
    Wu, L.
    Lu, L.
    Zhu, W.
    Gu, Y.
    NEOPLASMA, 2016, 63 (04) : 523 - 531
  • [32] Plasma 25-Hydroxyvitamin D3 and Bladder Cancer Risk According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study
    Amaral, Andre F. S.
    Mendez-Pertuz, Marinela
    Munoz, Alberto
    Silverman, Debra T.
    Allory, Yves
    Kogevinas, Manolis
    Lloreta, Josep
    Rothman, Nathaniel
    Carrato, Alfredo
    Rivas del Fresno, Manuel
    Real, Francisco X.
    Malats, Nuria
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (24): : 1897 - 1904
  • [33] Inhibition of multiple myeloma tumor growth and FGFR3 by the aurora-angiogenesis inhibitor ENMD-981693
    Hembrough, Todd A.
    Chen, Xiaoru
    Burke, Patricia A.
    Swartz, Glenn M.
    Bengali, Kathleen
    Brokx, Richard
    LaVallee, Theresa M.
    Bray, Mark R.
    BLOOD, 2007, 110 (11) : 366A - 366A
  • [34] FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases
    Turo, Rafal
    Harnden, Patricia
    Thygesen, Helene
    Fleischmann, Achim
    Thalmann, George N.
    Seiler, Roland
    Cross, William R.
    Knowles, Margaret A.
    JOURNAL OF UROLOGY, 2015, 193 (01): : 325 - 330
  • [35] FGFR3 can predict tumor outcome in patients with superficial urothelial cancer
    Mhawech, P
    Herrmann, F
    Fischer, G
    Beck, A
    Cheney, RT
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (04) : 632 - 632
  • [36] Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer
    Borkowska, Edyta Marta
    Traczyk-Borszynska, Magdalena
    Kutwin, Piotr
    Pietrusinski, Michal
    Jablonowski, Zbigniew
    Borowiec, Maciej
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 907 - 915
  • [37] FGFR3 mutation analysis in urine samples can be used as marker of bladder cancer detection
    Alameda, F.
    Segales, L.
    Lorenzo, M.
    Juanpere, N.
    Soler, I.
    Lloveras, B.
    Lloreta, J.
    Hernandez-Llodra, S.
    VIRCHOWS ARCHIV, 2017, 471 : S270 - S270
  • [38] FGFR3 mutations as classifier of tumor progression and specific survival in T1G3 urothelial cell carcinoma of the bladder
    Bakkar, A
    Wallerand, H
    Vordos, D
    Salomon, L
    Saint, F
    Swieb, S
    Abbou, CC
    de Medina, SGD
    Chopin, DK
    JOURNAL OF UROLOGY, 2005, 173 (04): : 248 - 248
  • [39] Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q
    Lindgren, D
    Liedberg, F
    Andersson, A
    Chebil, G
    Gudjonsson, S
    Borg, Å
    Månsson, W
    Fioretos, T
    Höglund, M
    ONCOGENE, 2006, 25 (18) : 2685 - 2696
  • [40] Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q
    D Lindgren
    F Liedberg
    A Andersson
    G Chebil
    S Gudjonsson
    Å Borg
    W Månsson
    T Fioretos
    M Höglund
    Oncogene, 2006, 25 : 2685 - 2696
12345